AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04513691 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: EOS Calculator
Description: Neonatal Early-Onset Sepsis Risk Calculator which is a tool that determines the risk of EOS for a particular newborn by looking at maternal risk factors and the newborn's clinical picture as opposed to just laboratory tests alone
Study NCT00422279 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nobel Replace Tapered Groovy
Description: Bone inductive implant placed in supralveoral position or extraction site
Study NCT03707171 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Any hypoglycemic drugs except glucagon-like peptide type 1 (GLP-1) analogue.
Study NCT03380884 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-magnitude high-frequency vibration (LMHFV)
Description: Low-magnitude high-frequency vibration (LMHFV) is a biophysical intervention that provides non-invasive, systemic mechanical stimulation and has been reported to have no adverse effect.
Study NCT02141659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-385
Description: TAK-385 Tablets.
Study NCT03124225 — intervention group
Intervention type: DRUG
Intervention: DMARD
Study NCT03689218 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Maamta (Nutritious Food Supplement)
Description: Pregnant women will receive 30 sachets of Maamta during pregnancy and first six months of lactation.
Study NCT03689218 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Wawamum (Lipid-Based Nutrient Supplement)
Description: Children 6-24 months will receive 30 sachets of Wawamum every month during the study.
Study NCT03618030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRC-063 oral capsules
Description: Daily dose
Study NCT03618030 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsules
Description: Daily dose
Study NCT01966731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Description: Hydroxyurea will begin at 15-20 mg/kg PO daily. Six months of treatment will be given at the fixed dose, followed by another six months with dose escalation (2.5-5.0 mg/kg increments every 8 weeks) as tolerated to 20-30 mg/kg/day or MTD. The dose escalation phase will continue through the 12-month evaluation, after which hydroxyurea will continue in maintenance phase until the common treatment termination date. The daily dose will be calculated using available capsule sizes and a goal of 15-20 (17.5 ± 2.5) mg/kg/day based on weight. After 6 months of treatment, hydroxyurea will be titrated according to myelosuppression, and will be increased to 20-30 mg/kg/day or the maximum tolerated dose (MTD). Hydroxyurea dose escalation will occur in 5.0 ± 2.5 mg/kg/day increments.
Study NCT01887548 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personality Traits Questionnaires
Description: Patients are required to fill out several personality traits questionnaires. The following personality traits scores would be collected: IBDQ, IBDQ-Emotional function score, IBDQ-Social function score, IBDQ-Bowel function score, IBDQ-Systemic symptom score, Neuroticism score, Lie (social conformity/desirability) score, Hospital anxiety score, Hospital depression score, Buss-Perry score, PA (physical aggression) score, VA (verbal aggression) score, A (anger) score, H (hostility) score.
Study NCT01887548 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Personality Traits Questionnaires
Description: Patients are required to fill out several personality traits questionnaires. The following personality traits scores would be collected: IBDQ, IBDQ-Emotional function score, IBDQ-Social function score, IBDQ-Bowel function score, IBDQ-Systemic symptom score, Neuroticism score, Lie (social conformity/desirability) score, Hospital anxiety score, Hospital depression score, Buss-Perry score, PA (physical aggression) score, VA (verbal aggression) score, A (anger) score, H (hostility) score.
Study NCT00629590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AzaSite®
Description: ophthalmic solution; 1 drop in each eye BID for two days, then 1 drop in each eye QD for \~12 days
Study NCT02612870 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sienna+ retro
Description: Sentinel node marking with Sienna+ retro-mamillary 1 day before surgery
Study NCT02612870 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sienna+ peri
Description: Sentinel node marking with Sienna+ peri-tumorally 1 day before surgery
Study NCT02612870 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sienna+ retro 4-6
Description: Sentinel node marking with Sienna+ retro-mamillary 4-6 days before surgery
Study NCT02612870 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sienna+ peri 4-6
Description: Sentinel node marking with Sienna+ peri-tumorally 4-6 days before surgery
Study NCT02612870 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Technetium 1
Description: Sentinel node marking with Technetium 1 day before surgery
Study NCT00728546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid (Rifinah)
Description: The dose of the re-challenged INH is followed by the results of the genotyping of NAT2 in each patient.
Study NCT04249882 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched to active medication
Study NCT04249882 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone
Description: 50 mg once a day
Study NCT04249882 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: 1 mg twice a day
Study NCT01228747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Description: Oral dose at flexible increase doses: 1000 mg/day or 2000 mg/day or 3000 mg/day, twice daily, 28 weeks
Study NCT01228747 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching oral placebo tablets twice daily for 28 weeks
Study NCT00697554 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HBV-MPL vaccine 208129
Description: 2-dose primary vaccination followed by 1 booster vaccination by intramuscular injection
Study NCT00697554 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Engerix™-B
Description: 3-dose primary vaccination followed by 1 booster vaccination by intramuscular injection of double doses
Study NCT01974466 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Goal A
Description: controled fluid therapy：10\~5ml/kg/h，crystalloid vs colloid 2:1 resuscitation target： fulfillment of two or more of four criteria:1. HR \<120 beats/min, 2.MAP 65-85 mm Hg, 3. urine output ≥1 ml/kg /h 4. HCT ≤35%.
Study NCT03467178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Nucleic Acid Synthesis Inhibitor
Study NCT03467178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Chemotherapy medication
Study NCT03467178 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Pegylated Liposomal Doxorubicin
Description: Chemotherapy medication
Study NCT03467178 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Gemcitabine
Description: Chemotherapy medication
Study NCT03467178 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Paclitaxel
Description: Chemotherapy medication
Study NCT01974466 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Goal B
Description: controled fluid therapy：10\~5ml/kg/h，crystalloid vs colloid 2:1 resuscitation target： fulfillment of all of the following criteria:~1 CVP 8-12 mmHg , 2.MAP 65-85 mm Hg, 3. urine output ≥0.5 ml/kg/h 4. ScvO2 ≤70%
Study NCT02857803 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Intervention of 30 minutes, 3 times a week until reaching 12 sessions.
Study NCT02857803 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Paper and Pencil
Description: Intervention of 30 minutes, 3 times a week until reaching 12 sessions.
Study NCT02857803 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Therapy
Description: Intervention of 30 minutes, 3 times a week until reaching 12 sessions.
Study NCT03337880 — intervention group
Intervention type: OTHER
Intervention: instrumental delivery
Description: the birth was assisted with an extractor.
Study NCT03358329 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: S8 Sinus Implant
Description: In-office bilateral placement of the S8 Sinus Implant (mometasone furoate, 1350 mcg) in the ethmoid sinuses
Study NCT02441205 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Intensity Interval training
Description: all subjects will undergo high intensity interval training 3 x per week for 10-12 weeks. the intervals of high-intensity (\~85% of maximal capacity) will be 5 to 10 bouts of 30 seconds at this intensity with rest periods in between intervals that range from 30 seconds to 2 minutes
Study NCT04448431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine
Description: 10 or 20 mg/day, capsules, orally
Study NCT04448431 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desvenlafaxine
Description: 50 mg/day capsules, orally
Study NCT02088827 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Inactivity
Description: Subjects will remain inactive (lying on a bed) for 4 hours.
Study NCT02088827 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Activity
Description: Subjects will spend 4 hours of inactivity (lying on a bed) broken up by 2 minutes of moderate intensity biking (on a stationary bike) every 20 minutes.
Study NCT00410865 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: INGN 201
Description: Mouth rinse given one time on the first day and two times on Days 2-5 of each course of INGN 201. The injection and rinse (first day of each cycle), or the two rinses (Days 2-5 of each cycle), will be separated by at least two hours.
Study NCT03605030 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Novel Lead Based Armboard
Description: Novel Lead Based Armboard
Study NCT03605030 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Standard Armboard
Description: Standard Armboard (without lead)
Study NCT05993286 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure Therapy
Description: At Week 0, the homework was to expose oneself to these sounds for 20 minutes a day, three days a week for three weeks.~At the Week 3 interview, the frequency and severity of the homework were adjusted based on the degree of improvement in the symptoms and the person's adherence to the instructions.
Study NCT05993286 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sound Therapy
Description: Participants were asked to listen to specifically modulated music for twenty minutes a day, three days a week, for the first three weeks. At the Week 3 assessment, if the patient reported no or little benefit in their misophonia symptoms, the instruction was modified (intensified) to listening to the same music for forty minutes a day, three days a week.
Study NCT05993286 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychoeducation
Description: A psychoeducation session, prepared by the research team was delivered by the investigator to each patient at the study intake.
Study NCT05993286 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Psychoeducation
Description: A psychoeducation session, prepared by the research team was delivered by the investigator to each patient at the study intake.
Study NCT05993286 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation
Description: A psychoeducation session, prepared by the research team was delivered by the investigator to each patient at the study intake.
Study NCT02646306 — intervention group
Intervention type: OTHER
Intervention: shoulder proprioceptive rehabilitation tool
Description: Using of this tool to measure which is the average error in reaching back in both healthy subjects and subjects with shoulder impingement syndrome starting from the assumption that the shoulder, through the articulation scapulothoracic, helps to determine direction and distance during the reaching of an object.
Study NCT04127656 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Amino Acid-Based Experimental Study Formula
Description: Amino Acid-Based Formula; fed ad libitum
Study NCT03890471 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Preoperative telephone call three days before surgery
Description: Patients will receive a provider-initiated telephone call three days before surgery. In order to standardize counseling across providers, each provider will use a telephone script addressing the following components: Purpose of the surgery, alternatives to the surgery, surgical benefits, surgical risk (such as infection, bleeding, injury to other organ systems), potential surgical complications (such as mesh erosion, voiding dysfunction, urinary retention requiring indwelling catheter), bowel complaints (such as nausea, vomiting, constipation, diarrhea), and postoperative expectations (such as Foley management, pain management, activity restrictions, and diet. The following ERAS-specific components will be incorporated into the counseling: management of chronic medical conditions, cessation of alcohol and tobacco, and daily exercise until surgery. Questions from patients and total counseling time will be recorded.
Study NCT01279902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab plus CHOP Immunochemotherapy
Description: The R-CHOP treatment will continue up to 3 cycles with interval of 21 days: Each cycle consists of rituximab 375mg/m2 (iv, on day 1), cyclophosphamide 750 mg/m2 (iv, on day 1), doxorubicin 50mg/m2 (iv, on day 1), vincristine 1.4mg/m2 (iv, on day 1), and prednisolone 100mg (po, on day 1-5).
Study NCT02462317 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: botulinum A toxin
Description: botulinum toxin injection
Study NCT02462317 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Baclofen
Description: baclofen oral tablet
Study NCT02462317 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo toxin
Description: placebo injection
Study NCT02462317 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo toxin
Description: placebo injection
Study NCT02462317 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo baclofen
Description: placebo oral tablet
Study NCT02462317 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo baclofen
Description: placebo oral tablet
Study NCT04572386 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: light cure 3m single bond universal bond
Description: light -cure universal bond
Study NCT04572386 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Self-cure universal bond (Palfique, Tokuyama, Japan)
Description: Self-cure universal bond with no light cure
Study NCT01650974 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HFNOT
Description: high flow nasal oxygen therapy
Study NCT01650974 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: HFNOT
Description: high flow nasal oxygen therapy
Study NCT02393417 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CANDIN
Description: Candida albicans Skin Test Antigen for Cellular Hypersensitivity
Study NCT02393417 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% Sodium Chloride Injection USP (non-preserved)
Study NCT01577303 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive bias modification training program variant 1
Description: Computerized, internet-based training program for implicit modification of cognitive bias of attention, variant 1. Participant is exposed to two words -- either neutral-negative, neutral-positive, or negative-positive -- for 500ms-1000ms, followed by a probe (\< or >) in the previous position of ONE of these words and is then asked to press the corresponding arrow button on a keyboard. A total of 192 word pairs are shown during a session, of one third is the neutral-negative, one third is neutral-positive, and one third is negative-positive. The probe always follows the more positive word.
Study NCT01577303 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive bias modification training program variant 2
Description: Computerized, internet-based training program for implicit modification of cognitive bias of attention, variant 2. Participant is exposed to a pair of words or a pair of faces -- either neutral-negative, neutral-positive, or negative-positive -- for 500ms-1000ms, followed by a probe (\< or >) in the previous position of ONE of these words or faces and is then asked to press the corresponding arrow button on a keyboard. A total of 96 word pairs and 96 face pairs are shown during a session. One third is neutral-negative, one third is neutral-positive, and one third is negative-positive. The probe always follows the more positive word or face.
Study NCT01577303 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBM training program variant 3
Description: Computerized, internet-based training program for implicit modification of cognitive bias of attention, variant 3. Participant is exposed to two words -- either neutral-negative, neutral-positive, or negative-positive -- for 500ms-1000ms, followed by a probe (\< or >) in the previous position of ONE of these words and is then asked to press the corresponding arrow button on a keyboard. A total of 192 word pairs are shown during a session. One third is neutral-negative, one third is neutral-positive, and one third is negative-positive. The probe always follows the more negative word.
Study NCT01577303 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBM training program variant 4
Description: Computerized, internet-based training program for implicit modification of cognitive bias of attention, variant 4. Participant is exposed to a pair of words or a pair of faces -- either neutral-negative, neutral-positive, or negative-positive -- for 500ms-1000ms, followed by a probe (\< or >) in the previous position of ONE of these words or faces and is then asked to press the corresponding arrow button on a keyboard. A total of 96 word pairs and 96 face pairs are shown during a session. One third is neutral-negative, one third is neutral-positive, and one third is negative-positive. The probe always follows the more negative word or face.
Study NCT01577303 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control training variant 1
Description: Computerized, internet-based training program for implicit modification of cognitive bias of attention, variant 1. Participant is exposed to a pair of words -- either neutral-negative, neutral-positive, or negative-positive -- for 500ms-1000ms, followed by a probe (\< or >) in the previous position of ONE of these words and is then asked to press the corresponding arrow button on a keyboard. A total of 192 word pairs are shown during a session. One third is neutral-negative, one third is neutral-positive, and one third is negative-positive. The probe follows the more positive word and the more negative word with equal frequency..
Study NCT01577303 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control training variant 2
Description: Computerized, internet-based control training program, variant 2. Participant is exposed to a pair of words or a pair of faces -- either neutral-negative, neutral-positive, or negative-positive -- for 500ms-1000ms, followed by a probe (\< or >) in the previous position of ONE of these words or faces and is then asked to press the corresponding arrow button on a keyboard. A total of 96 word pairs and 96 face pairs are shown during a session. One third is neutral-negative, one third is neutral-positive, and one third is negative-positive. The probe follows the more positive stimulus and the more negative stimulus with equal frequency.
Study NCT03875911 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mitomycin C
Description: Three delivery methods of Mitomycin-C in Trabeculectomy
Study NCT02144519 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Eating and Physical Activity
Description: Create partnerships with ASPs to help facilitate changes in programming to meet the National Afterschool Alliance's HEPA Standards.
Study NCT01435044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Description: Sofosbuvir 400 mg (2 × 200 mg tablets) administered orally once daily
Study NCT03254173 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mirtazapine 30 mg oral tablets
Description: Mirtazapine 30 mg oral tablets ( Remeron 30 mg oral tablets) , half tablet before sleep for 8 weeks
Study NCT03254173 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablets
Description: Placebo oral tablets , half tablet daily before sleep for 8 weeks
Study NCT04310644 — intervention group
Intervention type: OTHER
Intervention: No intervention planned, but all patients get our standart treatment
Description: Patients are selected from clinical Routine and get our standart Treatment based on their disease
Study NCT02620020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fasinumab
Description: Participants received fasinumab SC or IV, Q4W or Q8W.
Study NCT02620020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Participants received placebo matching to fasinumab SC or IV, Q4W or Q8W.
Study NCT00691665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olopatadine HCL Nasal Spray, 0.6%
Description: Olopatadine HCL Nasal Spray, 0.6% 2 sprays per nostril twice daily
Study NCT00691665 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone Propionate Nasal Spray, 50 mcg
Description: Fluticasone Propionate Nasal Spray, 50 mcg 2 sprays per nostril once daily